A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma.

ABSTRACT:

Background

Australian Government subsidisation of ipilimumab for the treatment of patients with metastatic melanoma was conditional on the sponsor entering a 'managed entry scheme' to assess the 2-year overall survival rate in metastatic melanoma patients who received ipilimumab in the first year of Pharmaceutical Benefits Scheme listing.

Methods

All unresectable stage IIIc / IV metastatic melanoma patients treated with at least one dose of ipilimumab therapy in Australia from the PBS listing date to a time point 12 months later (i.e. from 1-Aug-2013 to 31-Jul-2014) were invited to participate. Overall survival at 2 years post treatment initiation was measured, with Cox regression analysis used to examine the relationship between survival and patient baseline characteristics

SUBMITTER: Kim H 

PROVIDER: S-EPMC5810048 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature